Edyta Skladzinska Reyher, MD
Internal Medicine · Putnam Valley, NYNPI 1477622439
Payments from drug & device makers
Across 258 payments — averaging $17.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$768
- Boehringer Ingelheim$464
- Lilly USA, LLC$462
- Pfizer$381
- AstraZeneca$346
- Johnson & Johnson$316
- plus $2K from 25 others
What the payments were for
- Food & beverage$4,42399%
- Education$531%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 50 | $768 |
| Boehringer Ingelheim | 24 | $464 |
| Lilly USA, LLC | 25 | $462 |
| Pfizer | 23 | $381 |
| AstraZeneca(2 entities) | 20 | $346 |
| Johnson & Johnson | 16 | $316 |
| Novartis | 14 | $244 |
| AbbVie(2 entities) | 14 | $233 |
| Merck | 16 | $226 |
| Bayer | 10 | $201 |
| Abbott | 5 | $102 |
| Aurinia Pharma U.S., Inc. | 5 | $97 |
| E.r. Squibb & Sons, L.L.C. | 5 | $95 |
| Daiichi Sankyo Inc. | 4 | $59 |
| Exact Sciences | 3 | $58 |
| Kowa Pharmaceuticals America, Inc. | 3 | $57 |
| OPKO Pharmaceuticals, LLC | 3 | $53 |
| Fresenius USA Marketing, Inc. | 2 | $46 |
| Mylan Specialty L.p. | 2 | $42 |
| Astellas Pharma US Inc | 2 | $32 |
| Amarin Pharma, Inc. | 2 | $24 |
| Amneal Pharmaceuticals LLC | 1 | $23 |
| GSK | 1 | $20 |
| Vifor Pharma, Inc. | 1 | $20 |
| Dynavax Technologies Corporation | 1 | $20 |
| Akebia Therapeutics Inc | 1 | $15 |
| Ultragenyx Pharmaceutical Inc. | 1 | $15 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Biohaven Pharmaceuticals, Inc. | 1 | $15 |
| Otsuka America Pharmaceutical, Inc. | 1 | $13 |
How this compares
$4,477 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 76 | $79,352 |
| EliquisApixaban | 84 | $52,211 |
| JardianceEmpagliflozin | 52 | $38,854 |
| XareltoRivaroxaban | 48 | $38,847 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 34 | $33,614 |
| JanuviaSitagliptin Phosphate | 20 | $28,709 |
| XifaxanRifaximin | 17 | $27,175 |
| MounjaroTirzepatide | 25 | $25,657 |
| PrezcobixDarunavir/Cobicistat | 21 | $24,005 |
| FarxigaDapagliflozin Propanediol | 25 | $16,111 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 11 | $13,569 |
| EntrestoSacubitril/Valsartan | 13 | $11,048 |
| Spiriva RespimatTiotropium Bromide | 18 | $10,338 |
| SynjardyEmpagliflozin/Metformin Hcl | 11 | $9,668 |
| Incruse ElliptaUmeclidinium Bromide | 20 | $7,312 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $768 | $79,35276 claims |
| Johnson & JohnsonXarelto, Prezcobix | $316 | $62,85269 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Synjardy | $464 | $58,86181 claims |
| PfizerEliquis | $381 | $52,21184 claims |
| GSKTrelegy Ellipta, Incruse Ellipta, Breo Ellipta | $20 | $48,16869 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $346 | $29,68036 claims |
| MerckJanuvia | $226 | $28,70920 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $15 | $27,17517 claims |
| Lilly USA, LLCMounjaro | $462 | $25,65725 claims |
| NovartisEntresto | $244 | $11,04813 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $23 | $2,581214 claims |
| AbbVieSynthroid | $233 | $1,34817 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Putnam Valley
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
- Robert CupeloEast Syracuse$10.6M
- Patrick ReaganRochester$9.4M
- Sally LauNew York$8.4M
- Angela BrancheRochester$7.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.